These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 26275476

  • 1. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC, Neal JW, Niu XM, Wakelee HA.
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN, Goss GD.
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 4. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [Abstract] [Full Text] [Related]

  • 5. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

  • 6. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.
    Clin Cancer Res; 2015 Dec 15; 21(24):5439-44. PubMed ID: 26672084
    [Abstract] [Full Text] [Related]

  • 7. ALK inhibitors and advanced non-small cell lung cancer (review).
    Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C.
    Int J Oncol; 2014 Aug 15; 45(2):499-508. PubMed ID: 24889366
    [Abstract] [Full Text] [Related]

  • 8. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK, Kim TM, Koh Y, Lee SH, Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, Heo DS, Bang YJ.
    Lung Cancer; 2012 Aug 15; 77(2):460-3. PubMed ID: 22622260
    [Abstract] [Full Text] [Related]

  • 9. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar 15; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 10. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Mok TS, Wu YL.
    Clin Cancer Res; 2014 Mar 01; 20(5):1383-92. PubMed ID: 24443522
    [Abstract] [Full Text] [Related]

  • 11. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
    Somasundaram A, Socinski MA, Burns TF.
    Expert Opin Pharmacother; 2014 Dec 01; 15(18):2693-708. PubMed ID: 25381900
    [Abstract] [Full Text] [Related]

  • 12. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A.
    Anticancer Res; 2015 Nov 01; 35(11):5797-806. PubMed ID: 26504000
    [Abstract] [Full Text] [Related]

  • 13. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 01; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 14. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.
    Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, Normanno N, Morabito A.
    Expert Rev Anticancer Ther; 2013 Oct 01; 13(10):1207-18. PubMed ID: 24134422
    [Abstract] [Full Text] [Related]

  • 15. Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.
    Marquez-Medina D, Popat S.
    Future Oncol; 2016 Mar 01; 12(6):815-25. PubMed ID: 26829230
    [Abstract] [Full Text] [Related]

  • 16. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC, Lin CC, Yang JC.
    Curr Opin Oncol; 2015 Mar 01; 27(2):94-101. PubMed ID: 25611025
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C.
    Int J Cancer; 2012 Sep 01; 131(5):E822-9. PubMed ID: 22161771
    [Abstract] [Full Text] [Related]

  • 18. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 19. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ, Ou SH.
    Chin Clin Oncol; 2015 Jun 15; 4(2):20. PubMed ID: 26112806
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J, Smith KH, Bramlage P.
    Int J Cancer; 2016 Jun 01; 138(11):2549-61. PubMed ID: 26537995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.